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Abstract Genetic factors importantly contribute to
migraine. However, unlike for rare monogenic forms of
migraine, approaches to identify genes for common forms
of migraine have been of limited success. Candidate gene
association studies were often negative and positive results
were often not replicated or replication failed. Further, the
signiﬁcance of positive results from linkage studies
remains unclear owing to the inability to pinpoint the genes
under the peaks that may be involved in migraine. Prob-
lems hampering these studies include limited sample sizes,
methods of migraine ascertainment, and the heterogeneous
clinical phenotype. Three genome-wide association studies
are available now and have successfully identiﬁed four new
genetic variants associated with migraine. One new variant
(rs1835740) modulates glutamate homeostasis, thus inte-
grates well with current concepts of neurotransmitter dis-
turbances. This variant may be more speciﬁc for severe
forms of migraine such as migraine with aura than
migraine without aura. Another variant (rs11172113)
implicates the lipoprotein receptor LRP1, which may
interact with neuronal glutamate receptors, thus also pro-
viding a link to the glutamate pathway. In contrast,
rs10166942 is in close proximity to TRPM8, which codes
for a cold and pain sensor. For the ﬁrst time this links a
gene explicitly implicated in pain related pathways to
migraine. The potential function of the fourth variant
rs2651899 (PRDM16) in migraine is unclear. All these
variants only confer a small to moderate change in risk
for migraine, which concurs with migraine being a
heterogeneous disorder. Ongoing large international col-
laborations will likely identify additional gene variants for
migraine.
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Introduction
Migraine is a common neurological disorder affecting
between 10 and 20% of the population [1]. The clinical
presentation is heterogeneous and includes recurrent
headache attacks, associated symptoms of vegetative dis-
turbance, and hypersensitivity of various functional sys-
tems of the nervous system [1, 2]. About one-third of
migraineurs further experience transient neurological
symptoms mostly involving the visual system prior to or
during a migraine attack, which are known as migraine
aura [2]. The International Headache Society (IHS) has
established gold-standard criteria for the diagnosis of
migraine [3]. While migraines with aura (MA) and without
aura (MO) are the most common forms, the IHS also
acknowledges, for example, certain forms lacking one
diagnostic criterion as probable migraine as well as rare
familial monogenetic forms.
Heredity has been shown to play an important role in
migraine pathogenesis. About 50% of affected individuals
have a ﬁrst-degree relative also suffering from migraine
[4–6]. In addition, family and twin studies support the idea
of MO and MA being different phenotypes of the same
entity, with a heritability ranging from 33 to 57% [5, 7, 8].
The broad clinical spectrum of migraine and the results
from heritability studies have posted a challenge to the
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molecular genetics. For example, it is difﬁcult to ﬁnd a
pathophysiological link between a headache, which is not
symptomatic, and symptoms like nausea, photophobia, or
hypotension. In addition, it is unclear if some of the clinical
symptoms are more genetically determined and some are
more environmentally determined. On the contrary, dis-
secting the migraine phenotype into endophenotypes has
offered opportunities to better understand the pathophysi-
ological processes involved, facilitating the formulation of
hypotheses for genetic studies. For example, symptoms like
yawning (premonitory phase) and nausea (premonitory and
headache phase) point toward an involvement of dopamine
and have entailed genetic association studies of variants in
genes involved in dopamine metabolism [9]. Another
approach was to utilize epidemiological data for hypothesis
generation. The three- to fourfold higher prevalence of
migraine among women than men [10] as well as attacks
following a menstrual cycle pattern [11] suggested an
involvement of sex hormones and led to the investigation
of genetic variants in sex hormone receptor genes [12].
Aware of the limitations of these approaches, methods free
of assumptions have been employed mining the genome for
associations with the migraine phenotype or certain
migraine symptoms. These include linkage studies and
genome-wide association studies (GWAS). In contrast to
all approaches focusing on common forms of migraine,
investigations in rare familial forms of migraine, presenting
with a well circumscribed aura in the form of a hemipa-
resis/hemiplegia (familial hemiplegic migraine, FHM),
have been more successful in identifying underlying
genetic causes [13–15].
This manuscript does not aim at providing a complete
overview of genetic studies in migraine; this has compre-
hensively been done recently [16, 17]. This manuscript will
provide examples for different approaches used in migraine
genetics and then focus on results from the recently pub-
lished GWASs.
Familial hemiplegic migraine (FHM)
FHM is a rare, but severe form of migraine displaying an
autosomal dominant mode of transmission. The main
characteristic of FHM is a prolonged aura in the form of a
hemiparesis/hemiplegia presenting with the migraine
headache. FHM belongs to the group of channelopathies
and multiple genetic variants in three different genes
coding for neuronal ion channels have been identiﬁed as
causative. These genetic variants perturb the activity of the
channels, thus increasing neuronal excitability. In FHM
type 1 the affected gene is CACNA1A (chromosome
19p13), coding for a P/Q calcium channel [15], in FHM
type 2 the ATP1A2 gene (chromosome 1q23) is affected,
encoding a subunit of the Na
?/K
?-ATPase [13], and FHM
type 3 is caused by variants in the SCN1A gene (chromo-
some 2q24), coding for a sodium channel [14]. However,
patients with FHM only constitute a very small proportion
of all migraineurs and there is little evidence, that the
identiﬁed genes play a major role in common forms of
migraine [18]. This may also suggest that the ion channel
genes are only important for the aura and not the migraine
per se, since, in particular, the CACNA1A gene is also
implicated in other neurological disorders not associated
with migraine including episodic ataxia type 2 and spi-
nocerebellar ataxia type 6.
Candidate gene approaches
Candidate gene approaches have been a popular tool in
studying migraine genetics. Genes investigated are, for
example, implicated in serotonin and dopamine metabo-
lism, neurogenic inﬂammation, vascular function, and
hormone regulation.
Migraine is viewed as an inherited brain disorder,
characterized by neurotransmitter imbalances that lead to
neuronal dysfunctions [19]. The serotonergic system plays
an important role and alterations in serotonin metabolism
and in the processing of central serotonin-mediated
responses are typical features among migraineurs [20].
Following axonal release serotonin (5-HT) is rapidly taken
up again by the presynaptic serotonin transporter SLC6A4
(5-HTT) [21]. An insertion/deletion polymorphism in the
promoter region of the SLC6A4 gene, termed 5-HTTLPR
[22, 23] has functional impact on the synaptic clearing of
serotonin [24]. Ten studies in different populations have
investigated the association between the 5-HTTLPR gene
and migraine among Europeans and Asians [25]. Pooled
analyses did not ﬁnd an overall association; however, there
was some suggestion that gender and migraine aura status
may have modifying roles among Europeans.
Another neurotransmitter implicated in migraine path-
ogenesis is dopamine. Symptoms like yawning in the pre-
monitory phase and nausea in both the premonitory and
headache phase are ascribed to dopamine [26]. There is
also evidence from other pain disorders that dopamine
plays a role in central pain [27]. Further support for a role
of dopamine in migraine comes from studies showing that
anti-dopaminergic drugs exert beneﬁcial effects, when
administered during migraine attacks and from experi-
mental work showing that dopamine modulates the neu-
ronal ﬁring rate in the trigeminocervical complex [9].
Genetic association studies have mostly investigated vari-
ants in dopamine receptor genes and the dopamine beta-
hydroxylase gene; however, study results are conﬂicting
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unclear.
A ‘‘neurogenic inﬂammation’’ appears to be a key
mechanism in causing the migraine headache by activating
the trigeminal system [28]. Tumor necrosis factor-alpha
(TNF-alpha) is an important inﬂammatory cytokine and
modulator of immune responses. Its role in migraine has
been postulated based on reports of TNF-alpha concen-
tration changes in serum [29–31] and urine [32] among
migraineurs, as well as ﬁndings that TNF-alpha can stim-
ulate transcription of calcitonin gene-related peptide
(CGRP), which is pivotal in migraine pathophysiology
[33]. Variants in the genes coding for TNF-alpha and the
closely related TNF-beta have been shown to modulate
cytokine levels of TNF-alpha and TNF-beta [34, 35]
prompting investigations of various polymorphisms in
these genes with respect to their role in migraine. Among
the ten studies investigating variants in these genes, the
best evidence is available for the TNF-alpha -308G[A and
TNF-beta 252A[G polymorphisms. Pooled analyses did
not indicate an overall association with migraine [36].
While subgroup analyses suggested that associations may
differ among populations of non-Caucasian origin, these
ﬁndings only stem from few studies.
Migraine prevalence is three- to fourfold higher in
women than men [10]. Further, some women suffer from
migraine attacks presenting at speciﬁc times during the
menstrual cycle or experience changing patterns of attacks
during pregnancy or after menopause [11, 37]. Finally,
changes in estrogen levels can trigger migraine attacks [11,
37]. These ﬁndings have prompted studies investigating
variants in genes coding for proteins in sex hormone
receptor pathways and metabolism among migraineurs.
Pooled analyses of the available studies suggest that the
estrogen receptor-1 gene (ESR-1) 594 G[A and 325 C[G
polymorphisms can modify the risk for migraine, a ﬁnding
that does not differ between MA and MO [12]. In contrast,
the ESR-1 Pvu II C[T polymorphism and the progesterone
receptor (PGR) PROGINS insert polymorphism do not
appear to be associated with migraine.
The vasculature appears to play a special role in
migraine. For example, migraineurs carry an approximately
twofold increased risk for ischemic stroke compared to non-
migraineurs [38], some vasculopathies are frequently
observed among migraineurs such as livedo reticularis [39]
and Sneddon’s syndrome [40], and altered vascular reac-
tivity can be found among young migraineurs even in the
absence of other disorders [41]. These ﬁndings may be
linked to oxidative stress causing endothelial dysfunction
[42]. Speciﬁcally, certain gene variants in the methylene-
tetrahydrofolate reductase gene (MTHFR 677C[T poly-
morphism) and angiotensin-converting enzyme gene (ACE
D/I polymorphism) appear to importantly contribute to the
vascular oxidative stress response [42]. Consequently, an
association between the MTHFR 677C[T and ACE D/I
polymorphisms with migraine has been suggested [42].
Both are functional variants. The MTHFR 677TT genotype
impairs enzyme activity and carriers have increased
homocysteine levels. Carriers of the ACE II genotype
have ACE plasma levels half that of DD subjects, with ID
subjects having intermediate levels. Association studies
investigating the role of these variants in migraine were
controversial. Pooled analyses of 13 studies indicated that
the MTHFR 677TT genotype was associated with a 48%
increased risk for MA (pooled odds ratio [OR] = 1.48, 95%
conﬁdence interval [CI] 1.02–2.13), but not MO [43].
In contrast, pooled results from nine studies indicated that
the ACE II genotype was associated with a reduced risk
for MA (pooled OR = 0.71, 95% CI 0.55–0.93) and MO
(pooled OR = 0.84, 95% CI 0.70–0.99) [43].
Genome-wide approaches
In contrast to candidate gene association studies, genome-
wide approaches have been employed to identify potential
new chromosomal regions or genes that may associate with
migraine, migraine subtypes, or migraine features. These
are basically data mining techniques screening a part or the
whole genome. The two main methods employed are
linkage analyses that study pedigrees of migraineurs and
GWAS that investigate large populations of migraineurs
and non-migraineurs.
Linkage studies
Linkage analyses have identiﬁed several genetic loci for
overall migraine, MA, and MO. However, the underlying
genes from these chromosomal regions that may plausibly
alter risk of migraine have not yet been identiﬁed. Overall
migraine has been linked to chromosomes Xq24-28 [44],
6p12.2-21.1 [45], 19p13 [46], and 1q31 [47]; MA to 4q24
[48], 9q21-q22 [49], 11q24 [50], and 15q11-13 [51]; and
MO to 14q21.1-22.3 [52], and 4q21 [53].
Alternative phenotyping methods
Only two independent linkage studies from Iceland and
Finland describe an overlapping gene locus on chromo-
some 4 [48, 53]. However, the other studies have reported
many different loci, which is likely a reﬂection of the
genetic heterogeneity of migraine. The heterogeneous
migraine phenotype with a broad spectrum poses a par-
ticular challenge to genetic studies, which may in part
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clearly deﬁned individual features of migraine (‘‘endo-
phenotypes’’) may help to more consistently identify
genetic loci or genes involved in migraine [54]. For
example, employing trait component analysis and latent
class analysis has successfully linked certain chromosomal
regions to pulsating pain, phono-/photophobia, nausea, and
age at onset of migraine [44, 55, 56].
Genome-wide association studies
The ﬁrst GWAS in migraine was published by the Inter-
national Headache Genetics Consortium (IHGC) in 2010
[57] (Table 1). This was a two-stage association study
involving seven clinic-based case collections. In the dis-
covery stage 2,731 migraineurs all suffering from MA,
recruited from clinics in Finland, Germany, and the Neth-
erlands, were compared with 10,747 population-based
controls from the same countries. In the replication stage
an additional 3,202 cases from clinics in Denmark, the
Netherlands, and Germany as well as from the general
population in Iceland were available and compared to
40,062 population-based controls. Patients used for repli-
cation suffered either from MA or MO. Diagnoses were
made by headache experts using a combination of ques-
tionnaires and direct interviews based on the 2004 IHS
diagnostic criteria [3]. The following diagnostic subgroups
were analyzed: overall migraine, MA only, MA and MO,
and MO only.
In the discovery stage, 429,912 genetic variants were
genotyped in cases and controls utilizing an Illumina array.
Considering a genome-wide signiﬁcance threshold of
p B 5 9 10
-8, only one single nucleotide polymorphism
(SNP; rs1835740) was signiﬁcantly associated with overall
migraine. When using a more liberal threshold of
p B 5 9 10
-5 eleven SNPs were associated with migraine.
The minor allele of rs1835740 was associated with an
increased risk for migraine (OR = 1.23, 95% CI 1.15–1.32,
p = 5.38 9 10
-9). The population attributable risk for this
marker was estimated to be 10.7%. Replication of the
association at rs1835740 was successful and the meta-
analysis of results from all seven case–control samples
indicated an 18% increased risk for overall migraine
(OR = 1.18, 95% CI 1.13–1.24, p = 1.69 9 10
-11). In
subgroup analyses, the effects were stronger for patients
with MA than in those suffering from MO.
Findings from this GWAS lend support for a role of
glutamate in the pathophysiology of migraine, in particular
MA. rs1835740 is located between the genes MTDH and
PGCP, which are involved in glutamate homeostasis. The
study authors have also shown that the minor allele of
rs1835740 increases the expression levels of MTDH [57].
Further, previous studies in astrocytes have indicated that
MTDH downregulates SLC1A2, which codes for the major
glutamate transporter in the brain. This may lead to an
increase in the extracellular concentration of glutamate, the
major excitatory transmitter in the central nervous system.
Glutamate plays a role in trigeminovascular pain process-
ing [58] and may modulate the threshold for cortical
spreading depression [59], the putative biological correlate
of the aura [60].
In addition to rs1835740, eleven SNPs were associated
with migraine with p B 5 9 10
-5 (Table 1). Although
missing genome-wide signiﬁcance, these SNPs may have
potential implications for migraine. Nine of these are
located within or close to known genes including SMYD3,
INSIG2, TRPM8, MYLK4, ZNF311, SGCZ, NAV2, COG3,
and AQP9.
The second GWAS was performed by the Dutch-Ice-
landic (DICE) migraine genetics consortium [61]
(Table 1). In the discovery stage, ﬁve Dutch and one Ice-
landic population-based cohorts with 2,446 migraineurs
and 8,534 non-migraineurs were investigated. The repli-
cation samples derived from two population-based Dutch
cohorts and one Australian Twin study totaling 2,957 mi-
graineurs and 5,774 non-migraineurs. Migraine ascertain-
ment in the discovery cohorts was primarily by means of
questionnaires, and genotyping was performed utilizing a
variety of genotyping platforms. No SNP was associated
with migraine at the genome-wide level, 32 SNPs were
associated with migraine at p\10
-5. The best association
was seen for rs9908234 (p = 8.00 9 10
-8), which is
located in the nerve growth factor (NGF) gene. However,
neither this variant nor 18 other chosen variants out of the
32 variants showed associations in the replication cohorts.
In a further step, the authors explored associations of pre-
viously identiﬁed candidate gene variants for migraine with
migraine in the pooled discovery dataset. None of the
candidates was associated with migraine; however, in
gene-based analyses there was modest support for an
association of MTDH, implicated in the previous GWAS
[57], with migraine. Among the reasons potentially
explaining the inability to replicate ﬁndings from the dis-
covery cohorts are usage of different genotyping platforms,
methods of migraine ascertainment, and a lack of power,
despite the efforts of bringing together many cohorts.
The third GWAS was also performed to identify com-
mon genetic variants for migraine at the population level
[62] (Table 1). The study included three population-based
cohorts and information from the IHGC. The population-
based cohorts were the Women’s Genome Health Study
(WGHS), the Genetic Epidemiology of Migraine (GEM)
study, and the Study of Health in Pomerania (SHIP).
Migraine was either self-reported on questionnaires, diag-
nosed by headache experts or by a combination of both.
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Study Anttila et al. [57] Ligthart et al. [61] Chasman et al. [62]
Consortium name IHGC DICE (–)
Discovery samples
Names ?,?, LUMINA ERF, NESDA, NTR1, NTR2,
Rotterdam study, AGES study
WGHS
Origin Clinic-based; Finland, Germany,
The Netherlands
Population-based; The
Netherlands, Iceland
Population-based; US, European
descent
# of migraineurs/
non-migraineurs
2,731/10,747 2,446/8,534 5,122/18,108
Implicated gene
variants (gene)
a
rs1835740 (between MTDH and PGCP) rs9908234 (NGFR) rs2651899 (PRDM16)
rs2078371 (–)
rs10166942 (TRPM8)
rs17172526 (SEPT7)
rs2203834 (C8orf79)
rs13290757 (–)
rs11172113 (LRP1)
Replication samples
Names ?, ?, ?, LUMINA GEM, NTR3, ATM GEM, SHIP, IHGC
Origin Clinic- and population-based/Denmark,
Iceland, Germany, The Netherlands
Population-based/The Netherlands,
Australia
Population-based/The Netherlands,
Germany; clinic-based/Europe
# of migraineurs/
non-migraineurs
3,202/40,062 2,957/5,774 3,828/13,949
Replicated gene
variants
rs1835740 (between MTDH and PGCP) None rs2651899 (PRDM16) rs10166942
(TRPM8) rs11172113 (LRP1)
Meta-analysis
among
Discovery and replication samples Discovery samples Discovery and replication samples
Pooled results
a rs1835740: OR = 1.18, 95% CI 1.13–1.24,
p = 1.69 9 10
-11
rs9908234: p = 8.00 9 10
-8 rs2651899: OR = 1.11, 95% CI
1.07–1.15, p = 3.8 9 10
-9
rs10166942: OR = 0.85, 95% CI
0.82–0.89, p = 5.5 9 10
-12
rs11172113: OR = 0.90, 95% CI
0.87–0.93, p = 4.3 9 10
-9
Other implicated gene variants in discovery samples
Signiﬁcance
threshold
p B 5 9 10
-5 p\10
-5 p\5 9 10
-6
Gene variants
(genes)
a
rs12084862 (SMYD3) 31 other SNPs including: rs2078371 (–)
rs17528324 (INSIG2) rs11636768 (AGBL1) rs17172526 (SEPT7)
rs17862920 (TRPM8) rs10275320 (MACC1) rs2203834 (C8orf79)
rs2038761 (MYLK4) rs4939879 (LIPG) rs13290757 (–)
rs6456880 (ZNF311) rs4861775 (AGA)
rs7753655 (–) rs986222 (KIF2OB)
rs10888075 (near SGCZ) rs6107848 (BMP2)
rs10111769 (–) rs140174 (IGLL1)
rs2042600 (NAV2) rs1146161 (TSPAN2)
rs3794331 (COG3) rs4742323 (KDM4C)
rs473422 (near AQP9)
IHGC International Headache Genetics consortium, LUMINA Leiden University Migraine Neuro Analysis, DICE Dutch-Icelandic migraine
genetics consortium, ERF Erasmus Rucphen Family study, NESDA The Netherlands Study of Depression and Anxiety, NTR The Netherlands
Twin Registry, GEM Genetic Epidemiology of Migraine, ATM Australian Twin Migraine GWA study, WGHS Women’s Genome Health Study,
SHIP Study of Health in Pomerania, OR odds ratio, CI conﬁdence interval
a Results for overall migraine
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IHCG), Affymetrix arrays (SHIP), and iPLEX method
from Sequenom (GEM).
The discovery cohort consisted of 23,230 women of
European ancestry participating in the WGHS, which is a
large population-based cohort in the US. Among those
5,122 women reported migraine, while 18,108 did not. In
the genome-wide scan using age-adjusted logistic regres-
sion and assuming an additive genetic model, none of the
investigated SNPs were associated with migraine at
p\5 9 10
-8. However, seven independent genetic loci
had at least one SNP with an association of p\5 9 10
-6.
From each locus the authors selected the most signiﬁcant
SNP (Table 1). None of these seven SNPs was associated
with non-migraine headache. In addition, none of the seven
SNPs showed associations with migraine in non-additive
models, and no other SNP in the genome-wide scan
reached genome-wide signiﬁcance in non-additive models.
Finally, association analysis using imputed genotypes of
about 2.6 million SNPs identiﬁed the same seven loci as
found with the genotyped SNPs.
The seven chosen SNPs were evaluated in GEM (774
migraineurs, 942 non-migraineurs), SHIP (306 migrai-
neurs, 2,260 non-migraineurs), and IHGC (2,748 migrai-
neurs, 10,747 non-migraineurs). The effect estimates for
three of the SNPs (rs2651899, rs10166942, rs11172113)
pointed in the same direction and were comparable in
magnitude in all three replication studies as in the WGHS.
In the next step a meta-analysis of results for the seven
primary SNPs from all four cohorts was performed using a
ﬁxed-effects model, since there was no strong evidence of
heterogeneity. All three SNPs identiﬁed from the replica-
tion cohorts based on concordance in direction and mag-
nitude of association were associated with migraine at the
genome-wide level (rs2651899: OR = 1.11, 95% CI
1.07–1.15, p = 3.8 9 10
-9; rs10166942: OR = 0.85, 95%
CI 0.82–0.89, p = 5.5 9 10
-12; rs11172113: OR = 0.90,
95% CI 0.87–0.93, p = 4.3 9 10
-9). rs2651899 at 1p36.32
is located within the ﬁrst intron of PRDM16, rs10166942 at
2q37 is very close to the transcription start site for TRPM8,
and rs11172113 at 12q13.3 is in the ﬁrst intron of LRP1.
Interestingly TRPM8 was associated with migraine in the
ﬁrst IHGC GWAS at the sub-genome-wide level [57].
Gender-stratiﬁed analyses suggested that the association
seen at rs10166942 (TRPM8) may be speciﬁc for women
(meta-regression on gender p = 0.004). However, this
potential differential association did not appear to be
related to genetic variants in the ESR1 gene, as there was
no interaction between rs10166942 (TRPM8) and ESR1
variants. Further investigations looking at potential differ-
ences according to migraine aura status and features (for
example, unilateral pain location, pulsating pain quality,
photophobia, etc.) did not suggest that the associations seen
for any of the three variants differed by the presence or the
absence of aura or any of the features. Finally, the asso-
ciations seen for rs2651899 (PRDM16) and rs10166942
(TRPM8), but not rs11172113 (LRP1), were signiﬁcantly
associated with migraine compared to non-migraine head-
ache, underlining the speciﬁcity of these variants for
migraine.
TRPM8 codes for a cold and cold-induced burning pain
sensor [63] which is primarily expressed in sensory neu-
rons and the dorsal root ganglion [64]. TRPM8 is investi-
gated as a target in animal models of neuropathic pain [65].
Since migraine and neuropathic pain share some charac-
teristics [66], a role for TRPM8 in migraine as well as a
link between both pain syndromes is plausible.
LRP1 belongs to the lipoprotein receptor family and is
ubiquitously expressed [67]. LRP1 and NMDA glutamate
receptors co-localize on neurons and they interact. This is
particularly interesting since the previous GWAS by the
IHGC has identiﬁed a genetic variant involved in glutamate
homeostasis [57]. Both ﬁndings underline the role of glu-
tamate in migraine pathophysiology and integrate well with
pharmacological approaches targeting glutamate receptors
for migraine treatment [58].
A role for PRDM16 in migraine is unknown. Originally
identiﬁed at a chromosomal breakpoint associated with
myelodysplastic syndrome and leukemia [68], more recent
research has focused on its role in brown fat development
[69].
Implications
Endeavors to decipher the genetics of migraine have been
successful with respect to FHM; however, there is ongoing
debate about whether the genes involved (all coding for ion
channels) are speciﬁc for migraine headache, the accom-
panying hemiplegic aura, or possibly for both. In contrast,
attempts for common forms of migraine, although multi-
fold, were often ambiguous. Positive results from candidate
gene association studies have mostly not been robust, with
the exception, for example, for the MTHFR 677C\T
polymorphism, which shows an association with migraine
in pooled analysis of the available studies. Many other
genetic variants were not associated with migraine or
replication of positive results is either missing or failed.
Linkage studies produced some encouraging results, but it
remains unclear which genes under the linkage peaks may
be important for migraine. Reasons hampering an
unequivocal success of previous studies include limited
sample size, heterogeneity of the migraine phenotype as
well as study design and conduct.
Migraine GWASs have overcome some of these draw-
backs and advanced our understanding of migraine genetics
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have identiﬁed four new genetic variants that are associated
with migraine with genome-wide signiﬁcance and none of
the implicated genes has been a candidate in previous
genetic studies. Second, the role for three of the variants
may plausibly be integrated with current concepts of
migraine pathophysiology. rs1835740 modulates glutamate
homeostasis [57] and rs11172113 (LRP1)[ 62] may also
impact glutamate pathways through interaction of LRP1
receptors with NMDA glutamate receptors. Further, the
association at rs10166942 (TRPM8) for the ﬁrst time
implicates a gene in a pain related pathway in migraine.
Third, the available results are compatible with shared
pathophysiology among common forms of migraine, since
associations for rs2651899 (PRDM16), rs10166942
(TRPM8), and rs11172113 (LRP1) did not differ for MA
and MO [62]. Fourth, the results also suggest differences
between population-based and clinic-based forms of
migraine. While rs2651899 (PRDM16), rs10166942
(TRPM8), and rs11172113 (LRP1) appear most important
for common migraine (i.e., at the population level) [62],
rs1835740 may play the major role in more severe forms of
migraine (i.e., clinic-based populations) [57]. This agrees
with the fact that virtually all migraineurs in the IHGC study
suffered from MA [57], which is often considered more
severe than MO. However, the association of rs1835740
with MA may also underline the importance of glutamate
for the aura phenotype among migraineurs. Finally, the
effect estimates indicate that each of the variants only
confers a small to moderate change in risk for migraine
(Table 1). This agrees with migraine being a heterogeneous
disorder, where many gene variants work together to pro-
duce the migraine phenotype.
Outlook
Despite enormous efforts, the published GWASs can
‘‘only’’ claim to have identiﬁed four genetic variants to be
associated with migraine. This number appears small.
However, it is imperative to keep in mind the broad clinical
phenotype of migraine, which complicates the identiﬁca-
tion of genetic variants. In addition, we must consider that
the implicated genes are both new, replicated in indepen-
dent samples, and at the same time plausibly involved in
migraine pathophysiology.
Additional approaches in studying migraine genetics
include focusing on endophenotypes of migraine and
investigating larger numbers of migraineurs and non-
migraineurs. Trait component analysis and latent class
analysis have been used previously [44, 55, 56], and may
also be promising approaches for future GWASs. Further,
large international collaborations are ongoing aiming at
combining genome-wide genetic data on migraine to
increase the power to identify additional genetic variants in
migraine. Additional variants will likely be identiﬁed.
Finally, we need to understand that GWASs ‘‘only’’
investigate hundreds of thousands of common and known
gene variants. However, there is ample space in the gen-
ome that is not investigated. Hence, variants identiﬁed may
only be markers for migraine, which are in linkage dis-
equilibrium with the causative variants. Further, there may
be areas in the genome that are not well represented on the
GWAS platforms, but which may plausibly harbor variants
involved in migraine pathophysiology. In both scenarios it
may be useful to utilize DNA sequencing methods to
investigate certain genes or chromosomal regions to obtain
a complete map of all variants, including rare variants, in
these regions. This may facilitate the discovery of the
single best marker in a region or even identify new vari-
ants. Considering the large number of DNA base pairs to be
sequenced as well as the large number of individuals that
may have to investigated, high-throughput sequencing
methods may have to be used. However, the limitations
associated with each of the available platforms need to be
considered and the technology used must be tailored to the
speciﬁc projects.
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